ALG-097558

• Description :

  ALG-097558 is an orally active 3CLpro inhibitor. ALG-097558 demonstrates pan-coronavirus activity against various SARS-CoV-2 variants as well as other human coronaviruses (HCoVs) such as SARS-CoV-1, α-HCoV 229E, and β-HCoV OC43. ALG-097558 demonstrates potent inhibition with IC50s of 2 nM (SARS-CoV-2 3CLpro) and 6 nM (229E 3CLpro) . ALG-097558 demonstrates antiviral activity in the SARS-CoV-2 hamster infection model. ALG-097558 can be used for the study of viral infections[1].

• UNSPSC :

  12352005

• Target :

  SARS-CoV; Virus Protease

• Related Pathways :

  Anti-infection

• Field of Research :

  Infection

• Smiles :

  [H][C@@]12[C@@H]3C=C[C@H]([C@@]1([C@H](N(C2)C([C@H](C(C)(C)C)NC(C(F)(Cl)F)=O)=O)C(N[C@@H](C[C@@H]4CCNC4=O)C#N)=O)[H])C3

• Molecular Formula :

  C25H32ClF2N5O4

• Molecular Weight :

  540.00

• References & Citations :

  [1]Bardiot D, et al. Discovery and Preclinical Profile of ALG-097558, a Pan-Coronavirus 3CLpro Inhibitor. J Med Chem. 2025 Jul 10;68 (13) :13436-13454.

• Shipping Conditions :

  Room temperature

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• CAS Number :

  [2892287-29-3]